Labiotech.eu

Scenic Biotech Genetic Off Switch Cancer Rare Disease

News and Trends 5 Jun 2017

New Dutch Biotech Gets Funding to Find Genetic Off Switches

Scenic Biotech is applying a technology to identify first-in-class therapeutic targets that has secured it €6.5M in Series A. Scenic Biotech, founded in Amsterdam just this year, has raised €6.5M to exploit the potential of a technology to discover new types of disease-related genes with applications in cancer and rare genetic diseases. The company, created in […]

June 5, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Jun 2017

The Microscopic World of Bacteria Comes to Life with Sculpture

Aimee Lax is a British sculptor that explores the bizarre world of microscopic life by making beautiful sculptures that magnify their tiny size. “There’s a whole world out there that we never see, but it’s all here, it’s all real,” says Aimee Lax. Her piece Bacteriophages was included in the permanent exhibition Invisible You – The […]

June 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

brain organoids tissue engineering austria

News and Trends 2 Jun 2017

Austrian Researchers build an improved Mini-Brain to support Psychiatry

Researchers from Austria and the UK have made new advances in engineering brain-like structures. These lab-grown organoids mimic important functions of the real thing and could help improve understanding of mental illness and test new therapies. The Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) in Vienna is a pioneer of brain […]

June 2, 2017 - 2 minutesmins - By Denise Neves Gameiro

Startup Scout 2 Jun 2017

This French Biotech Wants to Reinvent DC-based Immunotherapies

This week we had the chance to visit both Grenoble and Liège, where the French-Belgian biotech hybrid PDC*line Pharma has its two headquarters. The company is progressing new types of immunotherapies based on dendritic cells (DCs). Mission: PDC*line Pharma emerged from an R&D program of the French Blood Bank (EFS, Etablissement Français du Sang), where […]

June 2, 2017 - 2 minutesmins - By Melanie De Almeida

Microbiome companies challenges opportunities

News and Trends 1 Jun 2017

Why Should we be Excited about the Emerging Microbiome Field?

A panel of experts at Microbiome Invest in London discussed the unlimited applications of the microbiome and how emerging companies may have a big impact on healthcare. During the past 10 years, the role of bacterial populations within our own organism has been studied, revealing a huge potential to develop new types of therapeutics. “The microbiome represents a […]

June 1, 2017 - 4 minutesmins - By External Contributor

News and Trends 1 Jun 2017

Next-Gen Drug Conjugates Bank €46M in Series B with American Investors

Bicycle Therapeutics has closed a massive fundraising round, raking in £40M (€46M) from American investors to launch clinical trials. Bicycle Therapeutics, the most recent company founded by the legendary academic-entrepreneur Greg Winter, is making a name for itself as a money magnet. Hot on the heels of a €1B deal with AstraZeneca last fall, the biotech […]

June 1, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 31 May 2017

Recruitment in Biotech is Broken, Here’s How to Fix it

How can changing the way your company hires, improve your business and result in better employees? Zocket brings a fresh approach to a long-standing challenge, to a systemic problem in our industry. There are multiple challenges when hiring new talent in a growing biotech. Given the rapid growth of the industry and the worldwide shortage […]

May 31, 2017 - 5 minutesmins - By External Contributor

Inthera Bioscience Protein Interactions Cancer

News and Trends 31 May 2017

Swiss Biotech raises €10M to Target Elusive Protein Interactions in Cancer

Inthera Bioscience has raised €9.6M in Series A to complete preclinical phase of its lead cancer program and expand its pipeline. Inthera Bioscience, located in Zurich, has closed a €9.6M (CHF 10.5M) Series A round led by Merck Ventures and backed by Novo Seeds and BioMedical Ventures, as well as a private investor. Members of Novo Seeds and […]

May 31, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 31 May 2017

German Biotech Enters the Clinic with Next-Generation Antibody for AML

Synimmune has hit the clinic with a first-in-human study of its Fc-optimized antibody FlySyn to treat patients with acute myeloid leukemia (AML). The German biotech Synimmune is developing next-generation anti-cancer antibodies to treat rare blood cancers. Its lead asset, FlySyn, is an antibody directed against the human fms-like tyrosine kinase 3 (FLT3) for the treatment of patients with […]

May 31, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 31 May 2017

Swiss Biotech raises €9M to Treat Sudden Hearing Loss in Phase III

Strekin has closed a Series C financing round that will fund the progression of its lead candidate for hearing loss to Phase III. Based in Basel, Strekin focuses on repurposing existing drugs by discovering new mechanisms of action. The company has now received €9.2M (CHF 10M) in Series C to fund the company’s activity until 2019 […]

May 31, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Interview 31 May 2017

Poll: Academia, Biotech or Another Career? How Industry Leaders Decided

Inspired by Philip’s interview with Patrick Baeuerle, who traversed academia, entrepreneurship and finance, I collected thoughts from biotech leaders on choosing a direction. Morten Sommer Professor of Systems Biology, TU Denmark Founder of Biosyntia, AntibioTx, Microlytic There’s a lot of freedom in academia that allows you to explore things that don’t have to be immediately […]

May 31, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 30 May 2017

Swiss Researchers get to the Genetic Bottom of Kidney Cancer

Researchers from the University of Zurich have established a new mouse model of kidney cancer that could further our understanding of this deadly disease. Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer and in roughly half of the patients with this disease the tumor develops metastasis and can’t be […]

May 30, 2017 - 2 minutesmins - By Melanie De Almeida

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

New Dutch Biotech Gets Funding to Find Genetic Off Switches

The Microscopic World of Bacteria Comes to Life with Sculpture

Austrian Researchers build an improved Mini-Brain to support Psychiatry

This French Biotech Wants to Reinvent DC-based Immunotherapies

Why Should we be Excited about the Emerging Microbiome Field?

Next-Gen Drug Conjugates Bank €46M in Series B with American Investors

Recruitment in Biotech is Broken, Here’s How to Fix it

Swiss Biotech raises €10M to Target Elusive Protein Interactions in Cancer

German Biotech Enters the Clinic with Next-Generation Antibody for AML

Swiss Biotech raises €9M to Treat Sudden Hearing Loss in Phase III

Poll: Academia, Biotech or Another Career? How Industry Leaders Decided

Swiss Researchers get to the Genetic Bottom of Kidney Cancer

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!